Intech Investment Management LLC Grows Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Intech Investment Management LLC grew its stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 70.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 31,571 shares of the biotechnology company's stock after buying an additional 13,060 shares during the quarter. Intech Investment Management LLC's holdings in Blueprint Medicines were worth $2,754,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of BPMC. Empirical Asset Management LLC purchased a new stake in Blueprint Medicines in the 4th quarter worth approximately $2,348,000. Stephens Inc. AR acquired a new position in shares of Blueprint Medicines in the fourth quarter worth about $321,000. Massachusetts Financial Services Co. MA boosted its stake in shares of Blueprint Medicines by 48.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 252,236 shares of the biotechnology company's stock worth $23,332,000 after acquiring an additional 82,693 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Blueprint Medicines by 2.4% during the 4th quarter. Bank of New York Mellon Corp now owns 303,432 shares of the biotechnology company's stock valued at $26,465,000 after acquiring an additional 7,101 shares during the period. Finally, KBC Group NV increased its stake in shares of Blueprint Medicines by 63.9% in the 4th quarter. KBC Group NV now owns 2,625 shares of the biotechnology company's stock valued at $229,000 after purchasing an additional 1,023 shares in the last quarter.

Blueprint Medicines Trading Up 7.4 %

Shares of NASDAQ BPMC traded up $6.55 during trading on Monday, reaching $95.27. The stock had a trading volume of 1,358,865 shares, compared to its average volume of 711,535. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. The company has a market cap of $6.09 billion, a P/E ratio of -88.21 and a beta of 0.58. Blueprint Medicines Co. has a fifty-two week low of $80.68 and a fifty-two week high of $121.90. The business's 50-day moving average price is $99.47 and its 200-day moving average price is $93.89.

Remove Ads

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. On average, equities research analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Kate Haviland sold 1,446 shares of the business's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total transaction of $159,407.04. Following the completion of the transaction, the chief executive officer now directly owns 149,378 shares of the company's stock, valued at $16,467,430.72. The trade was a 0.96 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $102.28, for a total value of $511,400.00. Following the completion of the sale, the director now directly owns 157,557 shares in the company, valued at $16,114,929.96. This represents a 3.08 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 29,334 shares of company stock valued at $3,103,512 in the last ninety days. Company insiders own 4.21% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Wedbush reiterated an "outperform" rating and set a $128.00 target price on shares of Blueprint Medicines in a research report on Friday, February 28th. Jefferies Financial Group started coverage on Blueprint Medicines in a research note on Monday, March 17th. They set a "buy" rating and a $135.00 price objective for the company. Morgan Stanley initiated coverage on Blueprint Medicines in a research note on Thursday. They issued an "equal weight" rating and a $100.00 price objective for the company. Needham & Company LLC reiterated a "buy" rating and issued a $133.00 target price on shares of Blueprint Medicines in a research report on Thursday, February 13th. Finally, Guggenheim restated a "buy" rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $124.95.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.